Adelaide Research & Scholarship: Search

Search

Results 1-10 of 10 (Search time: 0.003 seconds).

previous
1
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2013	Which TKI? An embarrassment of riches for chronic myeloid leukemia patients	Hughes, T.; White, D.
	2012	Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A	Blake, S.; Hughes, T.; Lyons, A.
	2009	Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo	Fraser, C.; Blake, S.; Diener, K.; Lyons, A.; Brown, M.; Hughes, T.; Hayball, J.
	2010	Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy	Hiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
	2009	Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?	Branford, S.; Vaz de Melo, J.; Hughes, T.
	2009	Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations	Muller, M.; Cortes, J.; Kim, D.; Druker, B.; Erben, P.; Pasquini, R.; Branford, S.; Hughes, T.; Radich, J.; Ploughman, L.; Mukhopadhyay, J.; Hochhaus, A.
	2009	Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet	Baccarani, M.; Cortes, J.; Pane, F.; Niederwieser, D.; Saglio, G.; Apperley, J.; Cervantes, F.; Deininger, M.; Gratwohl, A.; Guilhot, F.; Hochhaus, A.; Horowitz, M.; Hughes, T.; Kantarjian, H.; Larson, R.; Radich, J.; Simonsson, B.; Silver, R.; Goldman, J.; Hehlmann, R.
	2013	Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cells	Hiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
	2010	Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo	Fraser, C.; Lousberg, E.; Guerin, L.; Hughes, T.; Brown, M.; Diener, K.; Hayball, J.
	2017	CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors	Hughes, A.; Clarson, J.; Tang, C.; Vidovic, L.; White, D.; Hughes, T.; Yong, A.